Abstract
We examined the vaccine properties of a conventionally attenuated bovine herpesvirus type 1 (BHV-1) mutant strain A. This strain has a deletion that encompasses the glycoprotein E gene and may therefore be used as a marker vaccine. We compared strain A with a commercial live BHV-1 vaccine B. Calves were intranasally vaccinated with strain A or with vaccine B. Strain A was virtually avirulent for young calves. After challenge, vaccinated calves were protected against disease and virus shedding was considerably reduced. After dexamethasone treatment, strain A was not recovered, whereas vaccine B and challenge virus were. We conclude that strain A is suitable for inclusion in a vaccine and has the potential advantage of being used as a marker vaccine.
Publication types
-
Comparative Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Intranasal
-
Animals
-
Animals, Newborn
-
Antibodies, Viral / biosynthesis
-
Cattle
-
Cattle Diseases / immunology
-
Cattle Diseases / prevention & control*
-
Dexamethasone / pharmacology
-
Herpesviridae Infections / immunology
-
Herpesviridae Infections / prevention & control
-
Herpesviridae Infections / veterinary*
-
Herpesvirus 1, Bovine / genetics
-
Herpesvirus 1, Bovine / immunology*
-
Herpesvirus 1, Bovine / isolation & purification
-
Safety
-
Vaccination / veterinary*
-
Viral Envelope Proteins / immunology*
-
Viral Proteins
-
Viral Vaccines* / administration & dosage
-
Viral Vaccines* / immunology
Substances
-
Antibodies, Viral
-
Viral Envelope Proteins
-
Viral Proteins
-
Viral Vaccines
-
bovine herpesvirus type-1 glycoproteins
-
Dexamethasone